Advanced searches left 3/3

Peripheral Neuropathy - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 15 January 2023

* If you want to update the article please login/register

Cryocompression for Bortezomib-Induced Peripheral Neuropathy Among Multiple Myeloma Patients

Peripheral Neuropathy: From baseline to 4 and 8 weeks after the introduction of cryocompression therapy, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -Cancer-Induced Neuropathy - A study of neuropathy based on patient-reported assessment of neuropathy based on the sensory, motor, and autonomic neuropathy scores has been analyzed by a physician. The change in physician graded assessment of peripheral neuropathy by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. 0 from baseline to 4 and 8 weeks after the launch of cryocompression therapy began. After 8 weeks of daily cryocompression therapy, we'll be able to determine the effect on sensory and motor nerve function by nerve conduction study and neuro-ultrasound. At baseline, week 4, week 8, and week 8, week 8, We will investigate the relationships among the peripheral nerve assessment tools with the patient reported results, from baseline to week 8.

Source link: https://clinicaltrials.gov/ct2/show/NCT03870451


Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy

After meeting the other research eligibility requirements, subjects will be randomized into one of two treatment arms within 3 weeks of starting the offending chemotherapy drugs. Arm 1 will be given INF twice a week for six weeks by the same treating physical therapist. Arm 2 will be given a standardized program of muscle stretching and strengthening exercises twice a week for six weeks under the supervision of treating physical therapist #1. The same assessment physical therapist who will perform baseline and at the end of weeks 3, 6, and 3 months after last physical therapy will use measures to measure peripheral neuropathy's presence and severity. Objectives based on standard results: u2022 The objective of this study is to determine the degree of neuropathy and distress among Arm 1 receiving INF therapy and those receiving standard care of muscle stretching and strengthening exercises based on standardized results. To compare arm 1 getting INF therapy to Arm 2 receiving a standard program of muscle stretching and strengthening exercises, compare the rate of any dose reductions and premature chemotherapy discontinuation rates due to peripheral neuropathy. Based on a patient satisfaction survey completed at the end of therapy, we can determine subject acceptability, burden, and satisfaction with the allocated physical therapy modality between the two groups.

Source link: https://clinicaltrials.gov/ct2/show/NCT03272919


A Pilot Study Using Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

To compare the tibial motor nerve ultrasound cross-sectional area between oxaliplatin-induced peripheral neuropathy patients and historical findings among healthy adults. To compare the clinical findings of healthy adults with oxaliplatin-induced peripheral neuropathy patients and historical data in healthy adults. Patients with oxaliplatin-induced peripheral neuropathy patients' findings in the same oxaliplatin-induced peripheral neuropathy patients can determine if the above changes in the nerve cross-sectional area correlate with nerve conduction study findings. Patients with oxaliplatin-induced peripheral neuropathy in the same oxaliplatin-induced peripheral neuropathy patients can determine if the above changes in nerve cross-sectional region correlate with intraepidermal nerve fiber density changes on skin biopsy. In the same oxaliplatin-induced peripheral neuropathy patients VII, we'll find out if the above changes in the nerve cross-sectional area correlate with nerve conduction study findings. Patients with peripheral neuropathy in the same oxaliplatin-induced peripheral neuropathy patients VIII, and it is unclear if the above changes in the nerve cross-sectional area correlate with changes on a self-reported neuropathy scale.

Source link: https://clinicaltrials.gov/ct2/show/NCT03958747


Evaluation of the Efficacy of Donepezil in the Treatment of Oxaliplatin-induced Peripheral Neuropathy: Proof of Concept Study

The use of oxaliplatin in the treatment of colorectal or pancreas cancer in cancer patients has resulted in severe sensorimotor neuropathy, decreasing the quality of life of cancer survivors. The purpose of this research is to determine the pharmacological safety of donepezil on cancer survivors with oxaliplatin-induced peripheral neuropathy. A research has found in healthy volunteers that didpezil reduced the pain threshold triggered by adrenal stimulation of the sural nerve with no adverse effects in clinics. In the same way, two studies in patients with neuropathic pain found that donepezil elevates the analgesic effects of gabapentin. Eventually, a case report showed an analgesic effect of donepezil in painful Alzheimer's disease patients. A preclinical review reported that donepezil caused antineuropathic symptoms in diabetic mice with neuropathic pain. According to the hypothesis, the use of donepezil may reduce the signs of OIPN, decreases the quality of life, and the emergence of comorbidities in cancer survivors. Patients with OIPN-related colorectal or pancreas cancer treatment with oxaliplatin-based chemotherapy for the treatment of colorectal or pancreas cancer and peripheral neuropathy of grade 222662. The QLQ-CIPN20, as the primary endpoint in our methodological approach, will help us to more accurately identify neuropathic signs and evaluate the therapeutic effects of donepezil on these conditions. After a minimum of 12 weeks of therapy, after a minimum of 12 weeks of therapy, a response rate will be determined only for Donepezil arm and compared between each treatment arm.

Source link: https://clinicaltrials.gov/ct2/show/NCT05254639


Use of Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer: a Randomized Controlled Trial

The purpose of this investigation is to determine the effect of cryocompression therapy on the occurrence and severity of taxane-induced peripheral neuropathy in gynecologic cancer patients receiving chemotherapy. Compression therapy will be administered using commercially available compression socks and disposable surgical gloves, and cryotherapy can be achieved by attaching bags of ice to the compression chambers. The FACT-NTX's sensory subscale will be included in baseline neuropathy surveys, which includes the Patient Neurotoxicity Questionnaire and the Functional Assessment of Cancer Therapy – Taxane. In addition, tactile sensation with the monofilament test at baseline and one month after completion of 6 cycles of chemotherapy and cryocompression will be evaluated. The key findings are the proportion of patients with PNQ grade C or higher and a decrease in tactile sensitivity from baseline based on the monofilament test. The investigators' hypothesis that cryocompression will reduce chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.

Source link: https://clinicaltrials.gov/ct2/show/NCT04563130


A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

Objective PRIMARY OBJECTIVE: I. Investigate whether CBD and THC:CBD can reduce CIPN symptoms in comparison to placebo using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group -Neurotoxicity Subscale among breast and colon cancer survivors using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group -I. Using the Functional Assessment of Cancer Therapy General among breast and colon cancer survivors with chronic CIPN, Evaluate the impact of CBD and THC:CBD as compared to placebo on quality of life. Contrasted to placebo, researchers with chronic CIPN used neuropathic and pain drugs by cancer patients with chronic CIPN during treatment with CBD and THC:CBD. THC and THC:CBD therapies' side effects are described. For chronic CIPN, Evaluate for predictors of response to CBD and THC:CBD. ARM I: Patients are given CBD orally on study. According to the study, patients are given CBD PO + THC PO. Patients are given a placebo placebo. ARM III: Patients are given a placebo placebo.

Source link: https://clinicaltrials.gov/ct2/show/NCT05672342


Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire CIPN20 motor subscale, the EORTC QLQ CIPN20 autonomic scale, and the full Common Terminology Criteria for Adverse Events neuropathy scale are among the various aspects of neuropathy as determined by the European Organization for Research and Treatment of Neuropathy. ARM I: Patients apply cannabidiol cream topically to diseased areas twice a day for 14 days. Patients then apply placebo cream topically to the affected areas BID for 14 days. Patients administer placebo cream topically to the affected areas BID for 14 days, according to ARM II.

Source link: https://clinicaltrials.gov/ct2/show/NCT05388058


Immunoglobulin M (IgM)-Anti-myelin-associated-glycoprotein(MAG) Peripheral Neuropathy Study: From Proper Assessment to Trial Needs - IMAGiNe Study-Lyon/Bicêtre

The aim of the IMAGiNe project-Lyon/Bicu00eatre is to prospectively gather baseline clinical data of 25 patients with IgM-anti-MAG monoclonal gammopathy-associated peripheral neuropathy in order to participate in the international IMAGiNe Study. Both in the Netherlands, the Maastricht University Medical Center and University Medical Center Utrecht will coordinate the IgM-RODS building.

Source link: https://clinicaltrials.gov/ct2/show/NCT03918421

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions